Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Biocon appoints Vishal Nayyar as Head – SCM and Amit Kaptain as Head Commercials - API

Dr. Mandaviya addresses Governing Council Meeting of the ICMR

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research

Briefs: SMS Pharmaceuticals and Vimta Labs

EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024

Cabinet approves post of director for National Institute for One Health

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA